Literature DB >> 16214105

Membrane perturbation effects of peptides derived from the N-termini of unprocessed prion proteins.

Mazin Magzoub1, Kamila Oglecka, Aladdin Pramanik, L E Göran Eriksson, Astrid Gräslund.   

Abstract

Peptides derived from the unprocessed N-termini of mouse and bovine prion proteins (mPrPp and bPrPp, respectively), comprising hydrophobic signal sequences followed by charged domains (KKRPKP), function as cell-penetrating peptides (CPPs) with live cells, concomitantly causing toxicity. Using steady-state fluorescence techniques, including calcein leakage and polarization of a membrane probe (diphenylhexatriene, DPH), as well as circular dichroism, we studied the membrane interactions of the peptides with large unilamellar phospholipid vesicles (LUVs), generally with a 30% negative surface charged density, comparing the effects with those of the CPP penetratin (pAntp) and the pore-forming peptide melittin. The prion peptides caused significant calcein leakage from LUVs concomitant with increased membrane ordering. Fluorescence correlation spectroscopy (FCS) studies of either rhodamine-entrapping (REVs) or rhodamine-labeled (RLVs) vesicles, showed that addition of the prion peptides resulted in significant release of rhodamine from the REVs without affecting the overall integrity of the RLVs. The membrane leakage effects due to the peptides had the following order of potency: melittin>mPrPp>bPrPp>pAntp. The membrane perturbation effects of the N-terminal prion peptides suggest that they form transient pores (similar to melittin) causing toxicity in parallel with their cellular trafficking.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214105     DOI: 10.1016/j.bbamem.2005.09.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time.

Authors:  Yao-Cheng Li; Luo Wei Rodewald; Christian Hoppmann; Ee Tsin Wong; Sylvain Lebreton; Pavel Safar; Marcel Patek; Lei Wang; Kenneth F Wertman; Geoffrey M Wahl
Journal:  Cell Rep       Date:  2014-11-20       Impact factor: 9.423

2.  Biomolecular engineering by combinatorial design and high-throughput screening: small, soluble peptides that permeabilize membranes.

Authors:  Ramesh Rathinakumar; William C Wimley
Journal:  J Am Chem Soc       Date:  2008-07-09       Impact factor: 15.419

3.  Kinetic models for peptide-induced leakage from vesicles and cells.

Authors:  August Andersson; Jens Danielsson; Astrid Gräslund; Lena Mäler
Journal:  Eur Biophys J       Date:  2007-02-02       Impact factor: 2.095

4.  Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation.

Authors:  Behnam Mohammadi; Luise Linsenmeier; Mohsin Shafiq; Berta Puig; Giovanna Galliciotti; Camilla Giudici; Michael Willem; Thomas Eden; Friedrich Koch-Nolte; Yu-Hsuan Lin; Jörg Tatzelt; Markus Glatzel; Hermann C Altmeppen
Journal:  Mol Neurobiol       Date:  2020-05-04       Impact factor: 5.590

Review 5.  Delivery of therapeutic oligonucleotides with cell penetrating peptides.

Authors:  Prisca Boisguérin; Sébastien Deshayes; Michael J Gait; Liz O'Donovan; Caroline Godfrey; Corinne A Betts; Matthew J A Wood; Bernard Lebleu
Journal:  Adv Drug Deliv Rev       Date:  2015-03-04       Impact factor: 15.470

6.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

7.  Antimicrobial activity of human prion protein is mediated by its N-terminal region.

Authors:  Mukesh Pasupuleti; Markus Roupe; Victoria Rydengård; Krystyna Surewicz; Witold K Surewicz; Anna Chalupka; Martin Malmsten; Ole E Sörensen; Artur Schmidtchen
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

Review 8.  Building Cell Selectivity into CPP-Mediated Strategies.

Authors:  Irene Martín; Meritxell Teixidó; Ernest Giralt
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.